Abstract
Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Current Signal Transduction Therapy
Title:Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Volume: 7 Issue: 2
Author(s): J. David Port
Affiliation:
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Abstract: Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Export Options
About this article
Cite this article as:
David Port J., Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure, Current Signal Transduction Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157436212800376645
DOI https://dx.doi.org/10.2174/157436212800376645 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Interlocked Systems in Nanomedicine
Current Topics in Medicinal Chemistry Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Olive Oil-related Anti-inflammatory Effects on Atherosclerosis: Potential Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Resident Cardiac Stem Cells
Current Pharmaceutical Design Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Adiponectin as a Regulator of Vascular Redox State: Therapeutic Implications
Recent Patents on Cardiovascular Drug Discovery Moderate Hypothermia in the Management of Severe Traumatic Brain Injury: A Good Idea Proved Ineffective?
Current Pharmaceutical Design Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Synthesis and Altered Biodistribution of 99mTc Labeled Vincristine in Animal Model
Current Medical Imaging Isothiocyanates as Cancer Chemopreventive Agents: Their Biological Activities and Metabolism in Rodents and Humans
Current Drug Metabolism Computer-Assisted Methods in Chemical Toxicity Prediction
Mini-Reviews in Medicinal Chemistry CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Healthspan and Longevity in Mammals: A Family Game for Cellular Organelles?
Current Pharmaceutical Design